Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review
Frequency of pain crises in the · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes frequency of pain crisis compared with placebo (very low certainty).
1 finding from 1 review
Severity of pain (use of opioid analgesics) · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes severity of pain (use of opioid analgesics) compared with placebo (very low certainty).
1 finding from 1 review
QoL of participants living with SCD and their caregivers · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute chest syndrome ( · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes frequency of sickle cell‐related complications: acute chest syndrome compared with placebo (very low certainty).
1 finding from 1 review
Haemoglobin status · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
1 finding from 1 review
Ulcer healing · people with diabetes and foot ulcers
It is very uncertain whether magnesium and vitamin E co‐supplementation changes ulcer healing (absolute change in individual parameters of ulcer… compared with placebo (very low certainty).
3 findings from 1 review
Ulcer healing (absolute change in individual parameters of ulcer dimensions over time: mean (SD) cm wound width reduction · people with diabetes and foot ulcers
It is very uncertain whether magnesium and vitamin E co‐supplementation changes ulcer healing (absolute change in individual parameters of ulcer… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found